Search - tctmd.com

Displaying 21 - 40 of 144

Sort: Relevancy | Date

News Conference News ESC 2019

Another Step Forward for Genotype-Guided Prescribing After PCI: POPular Genetics

Yael L. Maxwell

September 03, 2019

News Conference News ESC 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Michael O'Riordan

September 01, 2019

News Conference News ESC 2019

POPULAR AGE Supports Clopidogrel Over Ticagrelor in Elderly ACS Patients

Michael O'Riordan

August 31, 2019

News Conference News EuroPCR 2019

ROBOT-ACS: Real-World Data Reiterate Ticagrelor’s Safety

L.A. McKeown

May 31, 2019

Taking Ticagrelor? Frank, Proactive Patient Conversations are Needed to Help With Adherence

News Daily News

Taking Ticagrelor? Frank, Proactive Conversations are Needed to Help With Adherence

Yael L. Maxwell

May 17, 2019

News Conference News ACC 2019

No TREAT for Ticagrelor at 12 Months: Fibrinolysis Patients After STEMI Do Just as Well on Clopidogrel

Shelley Wood

March 19, 2019

News Conference News TCT 2018

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

Michael O'Riordan

September 24, 2018

News Conference News ESC 2018

GLOBAL LEADERS: Ticagrelor Monotherapy Fails to Beat Conventional DAPT After PCI

Michael O'Riordan

August 27, 2018

News Conference News EuroPCR 2018

Ticagrelor Doesn’t Carry Any Off-Target Effects Compared With Clopidogrel, Prasugrel

Yael L. Maxwell

May 30, 2018

News Daily News

One in Five ACS Patients Does Not Fill P2Y12 Inhibitor Prescription After PCI

Michael O'Riordan

May 21, 2018

News Conference News ACC 2018

PHARMCLO: Biggest Genotyping Trial to Date Suggests Better Outcomes After ACS, With Caveats

Yael L. Maxwell

March 14, 2018

News Conference News ACC 2018

TREAT: No Major Bleeds With Ticagrelor in ACS Patients After Fibrinolysis

Shelley Wood

March 11, 2018

Presentation TCT 2017

Debate: After PCI in ACS, Should DAPT Potency Be De-escalated Over Time? No, Based on HORIZONS-AMI, PLATO, PEGASUS, and Other Studies!

Presenter: John A. Bittl, Freek W.A. Verheugt, Gennaro Giustino

October 30, 2017

Presentation TCT 2017

Strengths and Limitations of Composite Endpoints (eg, EXCEL, PLATO, and Others)

Presenter: Roxana Mehran, Robert W. Yeh, Stuart J. Pocock

October 30, 2017

News Daily News

Bleeding and Ischemic Events Fluctuate Out to 1 Year Post-STEMI: HORIZONS-AMI

Yael L. Maxwell

October 03, 2017

News Daily News

New Performance and Quality Metrics for STEMI and NSTEMI Care

Michael O'Riordan

September 21, 2017

News Conference News ESC 2017

CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS

Todd Neale

August 30, 2017

News Daily News

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Michael O'Riordan

August 04, 2017

News Conference News EuroPCR 2017

Best Antiplatelet Therapy in Real-World PCI? European Registries Fuel the Debate

Caitlin E. Cox

May 22, 2017

TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After ACS Saves Money, Prevents Bleeding

News Conference News EuroPCR 2017

TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After PCI Saves Money, Prevents Bleeding in ACS

Yael L. Maxwell

May 16, 2017

Advertisement

Another Step Forward for Genotype-Guided Prescribing After PCI: POPular Genetics

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

POPULAR AGE Supports Clopidogrel Over Ticagrelor in Elderly ACS Patients

ROBOT-ACS: Real-World Data Reiterate Ticagrelor’s Safety

Taking Ticagrelor? Frank, Proactive Conversations are Needed to Help With Adherence

No TREAT for Ticagrelor at 12 Months: Fibrinolysis Patients After STEMI Do Just as Well on Clopidogrel

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

GLOBAL LEADERS: Ticagrelor Monotherapy Fails to Beat Conventional DAPT After PCI

Ticagrelor Doesn’t Carry Any Off-Target Effects Compared With Clopidogrel, Prasugrel

One in Five ACS Patients Does Not Fill P2Y12 Inhibitor Prescription After PCI

PHARMCLO: Biggest Genotyping Trial to Date Suggests Better Outcomes After ACS, With Caveats

TREAT: No Major Bleeds With Ticagrelor in ACS Patients After Fibrinolysis

Debate: After PCI in ACS, Should DAPT Potency Be De-escalated Over Time? No, Based on HORIZONS-AMI, PLATO, PEGASUS, and Other Studies!

Strengths and Limitations of Composite Endpoints (eg, EXCEL, PLATO, and Others)

Bleeding and Ischemic Events Fluctuate Out to 1 Year Post-STEMI: HORIZONS-AMI

New Performance and Quality Metrics for STEMI and NSTEMI Care

CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Best Antiplatelet Therapy in Real-World PCI? European Registries Fuel the Debate

TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After PCI Saves Money, Prevents Bleeding in ACS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content